BJU INTERNATIONAL, Vol. 96, Number 8, December 2005, 1163-1170
European Urology Update Series 2005:6

Genová terapie v urologii: způsoby přenesení teorie do praxe

CHRIS H. BANGMA, PIERRE MONGIAT, ROBERT KRAAIJ a ELLEN SCHENK-BRAAT
Department of Urology, Erasmus MC, Rotterdam, the Netherlands

LITERATURA

1 Rochester MA, Brewster SF. Genetics for urologists. *BJU Int* 2004; 94: 232–7
2 Walsh CE. Gene therapy progress and prospects: gene therapy for the hemophilias. *Gene Ther* 2003; 10: 999–1003
3 Christ GJ. Gene therapy treatments for erectile and bladder dysfunction. *Curr Urol Rep* 2004; 5: 52–60
4 Miles BJ, Shalev M, Aguilar-Cordova E *et al.* Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. *Hum Gene Ther* 2001; 12: 1955–67
5 Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. *J Virol* 1998; 72: 1844–52
6 Gonzalez R, Vereecque R, Wickham TJ *et al.* Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. *Gene Ther* 1999; 6: 314–20
7 Nicklin SA, White SJ, Watkins SJ, Hawkins RE, Baker AH. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. *Circulation* 2000; 102: 231–7
8 Magnusson MK, Hong SS, Boulanger P, Lindholm L. Genetic retargeting of adenovirus: novel strategy employing 'deknobbing' of the fiber. *J Virol* 2001; 75: 7280–9
9 Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. *J Virol* 2001; 75: 4176–83
10 Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. *Nat Biotechnol* 1996; 14: 1574–8
11 Gu DL, Gonzalez AM, Printz MA *et al.* Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism. evidence for reduced toxicity and enhanced antitumor activity in mice. *Cancer Res* 1999; 59: 2608–14
12 Haisma HJ, Pinedo HM, Rijswijk A *et al.* Tumor-specific gene transfer via an adenoviral vector targeted to the pancarcinoma antigen EpCAM. *Gene Ther* 1999; 6: 1469–74
13 Tillman BW, de Gruijl TD, Luykx-de Bakker SA *et al.* Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. *J Immunol* 1999; 162: 6378–83
14 Nakamura T, Sato K, Hamada H. Reduction of Natural adenovirus tropism to the liver by both ablation of fibercoxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. *J Virol* 2003; 77: 2512–21
15 Rubanyi GM. The future of human gene therapy. *Mol Aspects Med* 2001; 22: 113–42
16 Miller AD. The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy. *Curr Med Chem* 2003; 10: 1195–211
17 Zuber G, Zammut-Italiano L, Dauty E, Behr JP. Targeted gene delivery to cancer cells. directed assembly of nanometric DNA particles coated with folic acid. *Angew Chem Int Ed Engl* 2003; 42: 2666–9
18 Connor RJ, Engler H, Machemer T *et al.* Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. *Gene Ther* 2001; 8: 41–8
19 Kichler A. Gene transfer with modified polyethylenimines. *J Gene Med* 2004; 6 (Suppl. 1): S3–10
20 Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. *Gene Ther* 2001; 8: 341–8
21 Kraaij R, van Rijswijk AL, Oomen MH, Haisma HJ, Bangma CH. Specific Membrane Antigen (PSMA) is a tissuespecific target for adenoviral transduction of prostate cancer in vitro. *Prostate* 2005; 62: 253–9
22 Bangma CH, Kraaij R, Oomen MHTh, Van Rijswijk AL, De Ridder CM. Adenoviral mediated gene therapy for

prostate cancer. studies on vector tropism and payload. *Prostate Cancer Prostatic Dis* 2000; 3: S5

23 Gong MC, Chang SS, Watt F *et al.* Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. *Mol Urol* 2000; 4: 217–22

24 Haviv YS, Blackwell JL, Kanerva A *et al.* Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. *Cancer Res* 2002; 62 : 4273–81

25 van der Poel HG, Molenaar B, van Beusechem VW *et al.* Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. *J Urol* 2002; 168: 266–72

26 Gotoh A, Ko SC, Shirakawa T *et al.* Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. *J Urol* 1998; 160: 220–9

27 Cheng WS, Giandomenico V, Pastan I, Essand M. Characterization of the androgen-regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter. *Endocrinology* 2003; 144: 3433–40

28 Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3 PCA3), a highly prostate cancer-specific gene. *Urology* 2003; 62: 34–43

29 Pramudji C, Shimura S, Ebara S *et al.* In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. *Clin Cancer Res* 2001; 7: 4272–9

30 Lee SJ, Kim HSYuR, Lee K *et al.* Novel prostate-specific promoter derived from PSA and PSMA enhancers. *Mol Ther* 2002; 6: 415–21

31 Bahrenberg G, Brauers A, Joost HG, Jakse G. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. *Biochem Biophys Res Commun* 2000; 275: 783–8

32 Ganly I, Kirn D, Eckhardt G *et al.* A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. *Clin Cancer Res* 2000; 6: 798–806

33 DeWeese TL, van der Poel H, Li S *et al.* A phase I trial of CV706, a replicationcompetent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. *Cancer Res* 2001; 61: 7464–72

34 Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. *Cancer Res* 1997; 57: 2559–63

35 Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer. biological principles, risk management and future directions. *Nat Med* 2001; 7: 781–7

36 Kraaij R, Oomen MHA, van Rijswijk ALCT, de Ridder CMA, van der Linden RMM, Bangma CH. Adenovirusmediated expression of PTEN in the PC-346C human prostate cancer model induces growth suppression (Abstract). *Amer Soc Gene Ther* 2001

37 Nicholas TW, Read SB, Burrows FJ, Kruse CA. Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. *Histol Histopathol* 2003; 18: 495–507

38 Freytag SO, Khil M, Stricker H *et al.* Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. *Cancer Res* 2002; 62: 4968–76

39 Nasu Y, Bangma CH, Hull GW *et al.* Adenovirus-mediated interleukin-12 gene therapy for prostate cancer. Suppression of orthotopic tumor growth and preestablished lung metastases in an orthotopic model. *Gene Ther* 1999; 6: 338–49

40 Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. *Int J Cancer* 1997; 70: 183–7

41 Reynolds PN, Nicklin SA, Kaliberova L *et al.* Combined transductional and transcriptional targeting improves the specificity of transgene expression *in vivo*. *Nat Biotechnol* 2001; 19: 838–42

42 Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) *in vivo* is critically dependent on tumor expression of primary ad receptors. *Cancer Res* 2001; 61: 813–7

43 Fechner H, Haack A, Wang H *et al.* Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting *in vivo* indicating

anatomical vector barriers. *Gene Ther* 1999; 6: 1520–35
44 Ebara S, Shimura S, Nasu Y *et al.* Gene therapy for prostate cancer. Toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. *Prostate Cancer Prostatic Dis* 2002; 5: 316–25
45 Jongmans W, Tiemessen DM, Oosterwijk E, Mulders PE. Letter to: Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. *Cancer Res* 2003; 63: 1994–5
46 Jongmans W, van den Oudenalder K, Tiemessen DM *et al.* Targeting of adenovirus to human renal cell carcinoma cells. *Urology* 2003; 62: 559–65
47 Moiseyenko VM, Danilov AO, Baldueva IA *et al.* Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors. *Ann Oncol* 2005; 16: 162–8
48 Koike H, Tomita N, Azuma H *et al.* An efficient gene transfer method mediated by ultrasound and microbubbles into the kidney. *Gene Med* 2005; 7: 108–16
49 Ardelt P, Bohle A. Molecular aspects of bladder cancer IV. gene therapy of bladder cancer. *Eur Urol* 2002; 41: 372–80
50 Dumey N, Mongiat-Artus P, Devauchelle P *et al.* In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells. *Eur Urol* 2005; 47: 257–63
51 Ramesh N, Memarzadeh B, Ge Y, Frey D, VanRoey M, Rojas V, YuDC. Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. *Mol Ther* 2004; 10: 697–705
52 Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. *Proc Natl Acad Sci USA* 1994; 91: 4407–11
53 Zhang J, Ramesh N, Chen Y *et al.* Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. *Cancer Res* 2002; 62: 3743–50
54 Pagliaro LC, Keyhani A, Williams D *et al.* Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. *J Clin Oncol*, 2003; 21: 2247–53
55 Shalev M, Kadmon D, Teh BS *et al.* Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. *J Urol* 2000; 163: 1747–?1750
56 Herman JR, Adler HL, Aguilar-Cordova E *et al.* In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. *Hum Gene Ther* 1999; 10: 1239–49
57 Teh BS, Aguilar-Cordova E, Vlachaki MT *et al.* Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. *Oncologist* 2002; 7: 458–66
58 Kubo H, Gardner TA, Wada Y *et al.* Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. *Hum Gene Ther* 2003; 14: 227–41
59 Cheng WS, Kraaij R, Nilsson B *et al.* A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. *Mol Ther* 2004; 10: 355–64
60 Li X, Zhang YP, Kim HS *et al.* Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. *Cancer Res* 2005; 65: 1941–51
61 Shen ZJ, Wang H, Lu YL, Zhou XL, Chen SW, Chen ZD. Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. *BJU Int* 2005; 95: 890–4
62 Bivalacqua TJ, Deng W, Champion HC, Hellstrom WJ, Kadowitz PJ. Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the corpora cavernosa for erectile dysfunction. *Meth Mol Biol* 2004; 279: 173–85
63 Van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer research. *Prostate* 2000; 43: 263–71

Korespondence:
Chris H. Bangma,
Department of Urology,
Erasmus MC, Rotterdam,
the Netherlands.
e-mail:
h.j.vanalphen@erasmusmc.nl

Zkratky:
CAR, coxsackie adenoviral receptor; PSMA, prostate specific membrane antigen; PSCA, prostate specific stem-cell antigen; HSV-TK, herpes simplex virusthymidine kinase.